Background Neoadjuvant therapy is increasingly being used before surgery for localized
pancreatic cancer. Given the importance of completing multimodal therapy, the aim of this …

Background Neoadjuvant therapy may increase the rate of radical tumour resection in
patients with pancreatic cancer. Its impact on tumour recurrence has not been investigated …

Objective: The aim of the study was to identify the survival of patients with locally advanced
pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant …

Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of
patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a …

Objective: The aim of this study was to pool data from randomized controlled trials (RCT)
limited to resectable pancreatic ductal adenocarcinoma (PDAC) to determine whether a …

Background The disappointing results of surgical therapy alone of ductal pancreatic cancer
can only be improved using multimodal approaches. In contrast to adjuvant therapy …

Abstract Background and Objectives Conclusive evidence in favor of neoadjuvant therapy
for those with non‐metastatic pancreatic ductal adenocarcinoma (PDAC) is still lacking. The …

Background Several studies have suggested a survival benefit of neoadjuvant therapy
(NAT) for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic head. Data …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic ductal adenocarcinoma (PDAC) remains to be a therapeutic challenge as only
15%‐20% of all patients present with resectable tumor stages by the time of diagnosis. In the …